CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 21 enrolled
Drug / intervention
Depobupivacaine +2 moredrug
Likely dose
Depobupivacaine 166mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04284930
NCT04284930Phase 4Completed
CompareCT.gov

Prospective, Randomized, Controlled Comparison of Local Anesthetic Infusion Pump Versus DepoFoam Bupivacaine For Pain Management After Unilateral Deep Inferior Epigastic Perforator Free Flap Reconstruction

The Cleveland Clinic·interventional·Posted Feb 26, 2020·Updated Jan 7, 2021

In Brief

A Phase 4 clinical trial evaluating Depobupivacaine, OnQ pump, and 1 other intervention for Pain, Postoperative. Completed, enrolled 21 participants across 1 site.

Detailed Summary

Effective post surgical pain control in patients undergoing unilateral deep inferior epigastric perforator (DIEP) free flap reconstruction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Postoperative
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 26, 2020
Enrollment StartFeb 1, 2016
Primary CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.4 years ago

Interventions

Depobupivacainedrug

surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.

OnQ pumpdrug

group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.

0.25% Bupivacainedrug

group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.